COMMUNIQUÉS West-GlobeNewswire

Free Community Cookout in Frisco: Ally Medical ER Ribbon Cutting
24/09/2026
Ally Medical ER Frisco hosts an evening of free food, drinks, cotton candy, and family games on October 8th FRISCO, Texas, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ally Medical Emergency Room is welcoming Frisco residents to [...]
Parents in Distress: New Survey Highlights the Impact of Lost Sleep on Busy Parents
24/09/2026
Aeroflow Sleep’s new survey found that just 5% of parents are getting the recommended amount of sleep, and 86% of parents want their healthcare providers to share resources to overcome sleep challenges ASHEVILLE, N.C., [...]
Medevise Consulting to Host “Robotics in Ophthalmology” Workshop in New Orleans During AAO 2026
24/09/2026
Regulatory, reimbursement, and surgical robotics leaders will ask what it takes for robots to leapfrog today’s standard of care in eye surgery NEW ORLEANS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medevise Consulting today [...]
Persevere Therapeutics Announces Treatment of First Patient in its MIROC-1 Phase 2a Ovarian Cancer Clinical Trial
24/09/2026
CHESTERBROOK, PA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc., a clinical-stage oncology company developing misetionamide — a first-in-class inhibitor of MYC, historically viewed as undruggable and [...]
Kessler Foundation and UPnRIDE Launch Research Initiative to Advance What’s Possible for People with Disabilities
24/09/2026
Research collaboration will further advance the capabilities, functionality, and real-world user experience of UPnRIDE’s upright mobility platform WEST ORANGE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- UPnRIDE , the FDA- [...]
SK pharmteco Launches Catalyst Kit to Streamline Catalytic Reaction Development and Continuous Manufacturing Scale-Up
24/09/2026
New structured offering bridges the gap between catalyst screening, process optimization, and commercial-scale continuous flow manufacturing for RSMs, Intermediates, and APIs RANCHO CORDOVA, Calif., Sept. 24, 2026 ( [...]
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
24/09/2026
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion Company anticipates positive monthly operating cash flow by [...]
ŌURA Joins Workday Wellness, Giving Employers a New Way to Fund Oura Ring as a Flexible Benefit
24/09/2026
Employers can now fully fund, subsidize, or discount the world's leading smart ring for their workforce through Workday Benefits & Wellness SAN FRANCISCO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ŌURA, a leading health [...]
Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders
24/09/2026
Differentiated approach directly and selectively enhances TrkB activity, a central regulator of neuroplasticity New funds will advance lead programme KTX-0141 through IND/CTA-enabling studies and Phase 1/1b clinical [...]
Coloplast A/S - Financial Calendar 2026/27
24/09/2026
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations [...]
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
24/09/2026
One winner will receive a luxury Entegra Super C motorhome, Polaris XPEDITION, trailer, and $100,000 cash GILBERT, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness has launched one of the largest [...]
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
24/09/2026
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a [...]
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
24/09/2026
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth [...]
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
24/09/2026
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
24/09/2026
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical [...]
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
24/09/2026
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“ Scancell ”, or the “ Company ”), a late-stage clinical immuno-oncology company developing active [...]
La transformation stratégique soutient la performance de Roquette au premier semestre 2026
24/09/2026
La transformation stratégique soutient la performance de Roquette au premier semestre 2026 Croissance du chiffre d'affaires de +9 % à 2 586 M€ et progression de l'EBITDA Courant de +18 % à 337 M€. La performance a été [...]
Strategic Transformation Supports Roquette’s H1 2026 Performance
24/09/2026
Strategic Transformation Supports Roquette’s H1 2026 Performance +9% turnover growth to €2,586 million and +18% Current EBITDA increase to €337 million. Performance was supported by favorable volume and mix effects, the [...]
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
24/09/2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]

Pages